Research Article
Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam
Table 3
Factors associated with different types of lipodystrophy among HIV-infected patients in Dar es Salaam.
| | Characteristic | Lipoatrophy | Lipohypertrophy | Mixed lipodystrophy | | Yes | No | value | Yes | No | value | Yes | No | value |
| | Age categories (yrs) | | | | | | | | | | | ≤30 | 0 (0.0) | 51 (100.0) | 0.004 | 1 (2.0) | 50 (98.0) | 0.463 | 2 (3.9) | 49 (96.1) | 0.436 | | 31–40 | 13 (6.7) | 181 (93.3) | 6 (3.1) | 188 (96.9) | 13 (6.7) | 181 (93.3) | | 41–50 | 18 (13.4) | 116 (86.6) | 5 (3.9) | 129 (96.3) | 14 (10.4) | 120 (89.6) | | ≥51 | 11 (16.4) | 56 (83.6) | 0 (0.0) | 67 (100.0) | 6 (9.0) | 61 (91.0) | | Missing | 5 (33.3) | 15 (66.7) | 0 (0.0) | 20 (100.0) | 2 (9.5) | 19 (90.5) | | Gender | | | | | | | | | | | Male | 20 (17.1) | 97 (82.9) | 0.004 | 3 (2.6) | 114 (97.4) | 1.000 | 8 (6.8) | 109 (93.2) | 0.699 | | Female | 27 (7.7) | 322 (92.3) | 9 (2.6) | 340 (97.4) | 28 (8.0) | 321 (92.0) | | Education level | | | | | | | | | | | No formal education | 3 (11.1) | 24 (88.9) | 0.797 | 1 (3.7) | 26 (96.3) | 0.204 | 2 (7.4) | 25 (92.6) | 0.039 | | Primary education | 34 (9.6) | 322 (90.4) | 7 (2.0) | 349 (98.0) | 27 (7.6) | 329 (92.4) | | Secondary education | 9 (13.2) | 59 (86.8) | 4 (5.9) | 64 (94.1) | 3 (4.4) | 65 (95.6) | | College/university | 1 (6.7) | 14 (93.3) | 0 (0.0) | 15 (100.0) | 4 (26.7) | 11 (73.3) | | HAART use | | | | | | | | | | | On HAART | 42 (17.6) | 196 (82.4) | <0.001 | 9 (3.8) | 229 (96.2) | 0.142 | 35 (14.7) | 203 (85.3) | <0.001 | | HAART naïve | 5 (2.2) | 223 (97.8) | 3 (1.3) | 225 (98.7) | 1 (0.4) | 227 (99.6) | | Type of HAART used | | | | | | | | | | | Nevirapine based | 1 (3.2) | 30 (96.8) | 0.002 | 2 (6.5) | 29 (93.5) | 0.817 | 5 (16.1) | 26 (83.9) | 0.013 | | Efavirenz based | 15 (12.7) | 103 (87.3) | 4 (3.4) | 114 (96.6) | 11 (9.3) | 107 (90.7) | | Stavudine based | 26 (30.2) | 60 (69.8) | 3 (3.5) | 83 (96.5) | 17 (19.8) | 69 (80.2) | | Protease Inhibitor based | 0 (0.0) | 3 (100.0) | 0 (0.0) | 3 (100.0) | 2 (66.7) | 1 (33.3) | | Duration of HAART use | | | | | | | | | | | HAART naïve | 5 (2.2) | 223 (97.8) | <0.001 | 3 (1.3) | 225 (98.7) | 0.025 | 1 (0.4) | 227 (99.6) | <0.001 | | 24 months | 11 (18.3) | 49 (81.7) | 5 (8.3) | 55 (91.7) | 7 (11.7) | 53 (88.3) | | 24–48 months | 22 (14.8) | 127 (85.2) | 3 (2.0) | 146 (98.0) | 26 (17.4) | 123 (82.6) | | >48 months | 9 (31.0) | 20 (69.0) | 1 (3.4) | 28 (96.6) | 2 (6.9) | 27 (93.1) |
|
|
HAART: Highly Active Antiretroviral Therapy.
|
